VentriPoint Diagnostics (VPT) AGM 2025 summary

Opening remarks and agenda

• CEO opened the meeting, highlighted forward-looking statements, and set expectations for the session.

Financial performance review

• Navigated a challenging capital markets environment while completing a major development phase.

• Engaged in private placements to minimize dilution and maintain operational progress.

• Capital remains the key constraint for execution speed; active efforts underway to secure more funding.

• Revenue targets for 2026 are set to exceed CAD 1 million, with plans for rapid scaling.

Board and executive committee updates

• Joe Hostetter, an industry veteran, now leads the congenital heart defect program.

• Added Stuart Gall as an advisor to facilitate higher-level industry contacts.